scholarly journals Burden of Genital Warts in Colombia: An Observational Study

2020 ◽  
Author(s):  
Joaquin Gustavo Luna Rios ◽  
Monica Rojas ◽  
Miguel Cashat ◽  
Glorian Persaud Yen ◽  
Alexandra Altland ◽  
...  
Keyword(s):  
Primary Care ◽  
Resource Use ◽  
Primary Care Physicians ◽  
Healthcare Resource ◽  
Sexual Transmission ◽  
Genital Warts ◽  
Care Utilization ◽  
Healthcare Resource Use ◽  
Office Visits ◽  
Convenience Sample

Introduction: Genital warts are benign lesions caused by sexual transmission of human papillomavirus types 6 and 11, with significant impact on healthcare resource use and patients’ quality of life. Objective: To describe the epidemiology of genital warts in adults visiting a physician office for any reason, physician practice patterns, and healthcare resource use and costs in Colombia. Methods: Participants were a convenience sample of 53 physicians in 5 specialties: primary care (15), gynecology (24), urology (12), proctology (1), and dermatology (1). Physicians completed a survey and daily log of all patients 18-60 years old seen over 10 days in their practices in 2016-2017. The physician survey recorded genital warts consultation and management patterns. The daily log recorded patient demographic information and genital warts diagnosis. Results: Among 6,393 patients logged by physicians, the genital warts prevalence was 2.03% (95%CI 1.69–2.38) and incidence 1.30% (95%CI 1.02–1.58). Primary care physicians referred most of their genital warts cases for treatment (female: mean 63.3%, SD=44.8; male: mean 58.3%, SD=43.8). Treatment of non-resistant episodes (<6-month duration) lasted an average of 37.4 days (SD=29.4) and required an average of 4.0 (SD=1.9) office visits for females and 3.0 (SD=1.7) for males. The overall mean cost of an episode of care was USD558.13 (SD=507.30). Conclusion: Genital warts cases reported by most participant physicians were mainly direct-consult, but patients were typically treated by specialists. Much of the genital warts health care utilization and costs reported could be prevented by immunization with the quadrivalent or nonavalent HPV vaccine.

Burden of genital warts in Peru: an observational study

2018 ◽  
Vol 30 (3) ◽  
pp. 264-274 ◽  
Author(s):  
Patricia J García ◽  
Cesar P Carcamo ◽  
Maria Valderrama ◽  
Sayda La Rosa ◽  
Cerise James ◽  
...  
Keyword(s):  
Primary Care ◽  
Human Papillomavirus ◽  
Observational Study ◽  
Sexual Transmission ◽  
Genital Warts ◽  
Skin Lesions ◽  
Demographic Information ◽  
Convenience Sample ◽  
Referral Patterns ◽  
Patient Demographic Information

Genital warts (GW) are mucosal or skin lesions caused by sexual transmission of human papillomavirus (HPV). This study estimates the frequency of GW cases in physicians’ clinics and physicians’ usual practices of GW referral and diagnosis in Peru. Participants in this study were a convenience sample of 100 physicians in five specialties: primary care (17), gynecology (37), urology (10), dermatology (31), and infectious diseases (5). Physicians completed a survey and daily log of all patients aged 18–60 years seen over ten days in their offices located in Peru. The survey recorded GW referral patterns and the daily log recorded patient demographic information and GW diagnosis. Among 12,058 patients, the annual GW prevalence (95% confidence interval [CI]) was 2.28% (2.02–2.56) and cumulative incidence (95% CI) was 1.60% (1.38–1.84). Physicians reported that most GW patients were direct consult (73.5% of male and 67.9% of females) and physicians treated most GW patients themselves (73.4% of males and 76.7% of females). As reported, the most common reasons for referring were ‘serious cases requiring more specialized treatment’ (73.2% of male and 72.2% of female) and ‘lack of resources to treat’ (26.8% of male and 27.8% of female). We conclude that GW cases are commonly seen by physicians in Peru.

scholarly journals Estimating the burden of illness related to genital warts in the Philippines: a nationally representative cross-sectional study

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Lani Buenconsejo ◽  
Smita Kothari-Talwar ◽  
Karen Yee ◽  
Amit Kulkarni ◽  
Nuria Lara ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Visual Analogue Scale ◽  
Resource Use ◽  
Analogue Scale ◽  
Healthcare Resource ◽  
Genital Warts ◽  
The Philippines ◽  
Newly Diagnosed ◽  
Healthcare Resource Use ◽  
Men And Women

Abstract Background This study estimated genital warts prevalence, genital-warts-related healthcare resource use and costs, and self-reported human-papillomavirus-related psychosocial impact among male and female patients aged 18–60 years in the Philippines. Methods Prevalence was estimated using daily logs numbering genital warts patients treated by participating physicians in 4 Philippine regions over a 5-week period (09JUL2011-24SEP2012). Physicians also completed a survey assessing patient referral patterns, healthcare resource use, treatment, and follow-up care. Psychosocial impact was estimated using the human papillomavirus impact profile and the EQ-5D questionnaires. HIP and EQ-5D scores were compared according to the presence of GW (males) and HPV disease (females). CECA scores were also compared by gender and age groups. Results Overall genital warts prevalence was estimated at 4.78% (95% confidence interval [CI]: 4.58–4.98%) for men and women aged 18–60 years. Genital warts prevalence was 3.39% (95% CI: 3.13–3.65%) and 8.0% (95% CI: 7.69–8.31%) among women and men, respectively. Prevalence estimates were highest in infectious disease specialist practices 18.67% (95% CI: 18.66–18.69%). Two thirds of the 233 (69.14%) male and 166 (67.20%) female patients were newly-diagnosed genital warts cases. Median costs for genital warts diagnosis and treatment reached 7121 and 7000 Philippine pesos among men and women, respectively. In the Cuestionario Específico para Condiloma Acuminado questionnaire, no statistically significant differences between patients were observed. In the EQ-5D questionnaire, male genital warts patients reported lower mean visual analogue scale scores than those without genital warts (78.20 vs 86.34, p < 0.0001). Mean visual analogue scale score values and utility values were lower for women with human-papillomavirus-related diseases than those without (77.98 vs 78.93, and 0.84 vs 0.88, respectively). Conclusions Genital warts is prevalent in the Philippines; more than 60% of cases were newly diagnosed, contributing to high genital-warts-related healthcare resource costs. Diagnosis of genital warts and human papillomavirus negatively impacted psychosocial indices such as patient well-being and health-related quality of life.

scholarly journals Economic analysis of the prevalence and clinical and economic burden of medication error in England

2020 ◽  
pp. bmjqs-2019-010206 ◽  
Author(s):  
Rachel Ann Elliott ◽  
Elizabeth Camacho ◽  
Dina Jankovic ◽  
Mark J Sculpher ◽  
Rita Faria
Keyword(s):  
Primary Care ◽  
Medication Errors ◽  
Resource Use ◽  
Economic Burden ◽  
Secondary Care ◽  
Healthcare Resource ◽  
Annual Number ◽  
Healthcare Resource Use ◽  
Clinically Significant ◽  
Potentially Clinically Significant

ObjectivesTo provide national estimates of the number and clinical and economic burden of medication errors in the National Health Service (NHS) in England.MethodsWe used UK-based prevalence of medication errors (in prescribing, dispensing, administration and monitoring) in primary care, secondary care and care home settings, and associated healthcare resource use, to estimate annual number and burden of errors to the NHS. Burden (healthcare resource use and deaths) was estimated from harm associated with avoidable adverse drug events (ADEs).ResultsWe estimated that 237 million medication errors occur at some point in the medication process in England annually, 38.4% occurring in primary care; 72% have little/no potential for harm and 66 million are potentially clinically significant. Prescribing in primary care accounts for 34% of all potentially clinically significant errors. Definitely avoidable ADEs are estimated to cost the NHS £98 462 582 per year, consuming 181 626 bed-days, and causing/contributing to 1708 deaths. This comprises primary care ADEs leading to hospital admission (£83.7 million; causing 627 deaths), and secondary care ADEs leading to longer hospital stay (£14.8 million; causing or contributing to 1081 deaths).ConclusionsUbiquitous medicines use in health care leads unsurprisingly to high numbers of medication errors, although most are not clinically important. There is significant uncertainty around estimates due to the assumption that avoidable ADEs correspond to medication errors, data quality, and lack of data around longer-term impacts of errors. Data linkage between errors and patient outcomes is essential to progress understanding in this area.

scholarly journals Cohort study of healthcare use, costs and diagnoses from onset to 6 months after discharge for takotsubo syndrome in Sweden

BMJ Open ◽  
2019 ◽  
Vol 9 (2) ◽  
pp. e027814 ◽  
Author(s):  
Sara Wallström ◽  
Inger Ekman ◽  
Elmir Omerovic ◽  
Kerstin Ulin ◽  
Hanna Gyllensten
Keyword(s):  
Primary Care ◽  
Resource Use ◽  
Healthcare Costs ◽  
Healthcare Resource ◽  
Takotsubo Syndrome ◽  
Healthcare Resource Use ◽  
Direct Healthcare Costs ◽  
The Mean ◽  
Discharge From Hospital

ObjectiveLittle is known about the economic impact of takotsubo syndrome (TS) for patients and the health system after initial discharge from hospital. Therefore, the aim of this study was to describe the healthcare resource use and calculate direct healthcare costs for TS, from hospitalisation to 6 months after discharge, and explore the distribution of costs between TS and other diagnoses among patients with TS.Method, participants and settingCohort study investigating direct healthcare costs from hospitalisation, open specialised outpatient and primary care. Healthcare resource use during 6 months after diagnosis with TS was collected for 58 consecutive patients from the Regional Patient Register. Incidence-based direct healthcare costs, in 2015 values, were calculated using diagnosis-related group weights and unit costs from national statistics on healthcare costs.ResultsThe mean length of hospital stay was 10.2 days, index 6.4 and re-admissions 3.8 days. The mean number of follow-up encounters per patient was 15.6, of which two-thirds was specialised outpatient and one-third was primary care. This resulted in an average cost of €10 360. Of this, costs of €8026 (77.5%) occurred during encounters for which at least one of the registered conditions was cardiovascular. Costs differed little according to background characteristics.ConclusionThis study shows that patients utilise hospital, specialised outpatient and primary care after discharge for TS. Most direct healthcare costs relate to cardiac diagnoses. Patients with TS would probably benefit from a supportive follow-up programme after discharge from hospital.

Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort

2015 ◽  
Vol 43 (1) ◽  
pp. 88-96 ◽  
Author(s):  
Jeffrey D. Greenberg ◽  
Jacqueline B. Palmer ◽  
Yunfeng Li ◽  
Vivian Herrera ◽  
Yuen Tsang ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Resource Use ◽  
Healthcare Resource ◽  
The United States ◽  
Direct Costs ◽  
Healthcare Resource Use ◽  
Office Visits ◽  
Disease Modifying Drugs ◽  
Multivariable Regression

Objective.Direct costs of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) have not been well characterized in the United States. This study assessed healthcare resource use and direct cost of AS and PsA, and identified predictors of all-cause medical and pharmacy costs.Methods.Adults aged ≥ 18 with a diagnosis of AS and PsA were identified in the MarketScan databases between October 1, 2011, and September 30, 2012. Patients were continuously enrolled with medical and pharmacy benefits for 12 months before and after the index date (first diagnosis). Baseline demographics and comorbidities were identified. Direct costs included hospitalizations, emergency room and office visits, and pharmacy costs. Multivariable regression was used to determine whether baseline covariates were associated with direct costs.Results.Patients with AS were younger and mostly men compared with patients with PsA. Hypertension and hyperlipidemia were the most common comorbidities in both cohorts. A higher percentage of patients with PsA used biologics and nonbiologic disease-modifying drugs (61.1% and 52.4%, respectively) compared with patients with AS (52.5% and 21.8%, respectively). Office visits were the most commonly used resource by patients with AS and PsA (∼11 visits). Annual direct medical costs [all US dollars, mean (SD)] for patients with AS and PsA were $6514 ($32,982) and $5108 ($22,258), respectively. Prescription drug costs were higher for patients with PsA [$14,174 ($15,821)] compared with patients with AS [$11,214 ($14,249)]. Multivariable regression analysis showed higher all-cause direct costs were associated with biologic use, age, and increased comorbidities in patients with AS or PsA (all p < 0.05).Conclusion.Biologic use, age, and comorbidities were major determinants of all-cause direct costs in patients with AS and PsA.

scholarly journals 1227. A Survey Study of Healthcare Resource Use, and Direct and Indirect Costs, Among Females with an Uncomplicated Urinary Tract Infection in the United States

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S702-S703
Author(s):  
Jeffrey Thompson ◽  
Alen Marijam ◽  
Fanny S Mitrani-Gold ◽  
Jonathon Wright ◽  
Ashish V Joshi
Keyword(s):  
Primary Care ◽  
Urinary Tract ◽  
Resource Use ◽  
Healthcare Resource ◽  
Work Productivity ◽  
Indirect Costs ◽  
Direct Costs ◽  
Urgent Care ◽  
Healthcare Resource Use ◽  
Direct And Indirect Costs

Abstract Background Uncomplicated urinary tract infections (uUTI) account for a large proportion of primary care antibiotic (AB) prescriptions. This study assessed uUTI-related healthcare resource use (HRU) and costs in US females with a self-reported uUTI. Methods We surveyed US females aged ≥ 18 years who participated in web-based surveys (fielded August 28–September 28, 2020 by Dynata, EMI, Lucid/Federated, and Kantar Profiles). Participants had a self-reported uUTI ≤ 60 days prior, and took ≥ 1 oral AB for their uUTI. Those reporting signs of complicated UTI were excluded. HRU was measured via self-reported primary care provider (PCP), specialist, urgent care, emergency room (ER) visits, and hospitalizations. Direct costs were calculated as sum of self-reported and HRU monetized with Medical Expenditure Panel Survey estimates. Indirect costs were calculated via Work Productivity and Impairment metrics monetized with Bureau of Labor Statistics estimates. Participants were stratified by number of oral ABs prescribed (1/2/3+) and therapy appropriateness (1 AB [1st line/2nd line]/multiple [any line] AB) for most recent uUTI. Multivariable regression modeling was used to compare strata; 1:1 propensity score matching assessed uUTI burden vs matched population (derived from the 2020 National Health and Wellness Survey [NHWS]). Results In total, 375 participants were eligible for this analysis. PCP visits (68.8%) were the most common HRU. Across participants, there were an average of 1.46 PCP, 0.31 obstetrician/gynecologist, 0.41 urgent care and 0.08 ER visits, and 0.01 hospitalizations for most recent uUTI (Table 1). Total mean uUTI-related direct and indirect costs were &1289 and &515, respectively (Table 1). Adjusted mean total direct costs were significantly higher (Table 2) for participants in the ‘2 AB’ cohort vs the ‘1 AB’ cohort (&2090 vs &776, p &lt; 0.0001), and for the ‘multiple AB’ vs ‘1 AB, 1st line’ cohorts (&1642 vs &875, p=0.002). Participants in the uUTI cohort reported worse absenteeism (+15.3%), presenteeism (+46.5%), overall work impairment (+52.4%), and impact on daily activities (+50.7%) vs NHWS cohort (p &lt; 0.0001, Table 3). Table 1. Overall mean uUTI-related healthcare resource use, direct, and indirect cost data Table 2. Estimated uUTI-related direct costs stratified by (A) number of AB and (B) appropriateness of AB therapy used to treat last uUTI Table 3. Mean Work Productivity and Activity Impairment data for uUTI and NHWS cohorts Conclusion Inadequate treatment response, evident by multiple AB use, was associated with an increase in uUTI-related costs, including productivity loss. Disclosures Jeffrey Thompson, PhD, Kantar Health (Employee, Employee of Kantar Health, which received funding from GlaxoSmithKline plc. to conduct this study) Alen Marijam, MSc, GlaxoSmithKline plc. (Employee, Shareholder) Fanny S. Mitrani-Gold, MPH, GlaxoSmithKline plc. (Employee, Shareholder) Jonathon Wright, BSc, Kantar Health (Employee, Employee of Kantar Health, which received funding from GlaxoSmithKline plc. to conduct this study) Ashish V. Joshi, PhD, GlaxoSmithKline plc. (Employee, Shareholder)

Estimating the burden of genital warts in Taiwan

Sexual Health ◽  
2017 ◽  
Vol 14 (6) ◽  
pp. 485 ◽  
Author(s):  
Tsen-Fang Tsai ◽  
Smita Kothari-Talwar ◽  
Karen Yee ◽  
Amit Kulkarni ◽  
Nuria Lara ◽  
...  
Keyword(s):  
Resource Use ◽  
Healthcare Resource ◽  
Well Being ◽  
Genital Warts ◽  
Psychosocial Impact ◽  
Health Related Quality ◽  
Healthcare Resource Use ◽  
Related Quality ◽  
Health Related

Background This study aimed to estimate the prevalence of genital warts in Taiwan among those seeking healthcare, as well as genital-warts-related healthcare resource use and costs, and self-reported genital-warts-related psychosocial impact. Methods: Genital warts prevalence estimates were extracted from a daily record of patients examined from 31 October 2011 to 4 May 2012 by 67 physicians in Taiwan. Physicians recorded the total number of patients and genital warts patients seen daily for 2 weeks. These physicians also completed a survey regarding healthcare resource use, treatment, follow-up care, and referral patterns. Patient psychosocial impact was estimated using a self-administered survey. Results: The overall prevalence of genital warts in Taiwan was estimated at 1.1%, with a higher prevalence among men. A total of 146 genital warts case patients were included in the study (76 men, 70 women). Median costs for diagnosis and treatment were US$222 for male and US$351.8 for female patients. Male genital warts subjects reported a negative psychosocial impact on their well-being and health-related quality of life – psychosocial impact results are reported in the Supplementary Material file. Conclusions: Genital warts prevalence was higher among male patients; female patients incurred higher costs. Among men, genital warts had a negative psychosocial impact on well-being and health-related quality of life.

scholarly journals Correction to: Proactive integrated virtual healthcare resource use in primary care

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jolie N. Haun ◽  
Bridget A. Cotner ◽  
Christine Melillo ◽  
Vanessa Panaite ◽  
William Messina ◽  
...  
Keyword(s):  
Primary Care ◽  
Resource Use ◽  
Healthcare Resource ◽  
Healthcare Resource Use
Sign in / Sign up

Export Citation Format

Share Document